STAT+: Lars Fruergaard Jørgensen, CEO of Novo Nordisk, to step down as company seeks a turnaround
Lars Fruergaard Jørgensen is stepping down as Novo Nordisk CEO, with the company citing the stock's recent struggles.
LONDON — Lars Fruergaard Jørgensen, who led Novo Nordisk as it rode the boom of its obesity and diabetes medications to become one of the biggest players in pharma, only to see that success stall in recent months, is stepping down as CEO, the company said Friday.
Jørgensen, who’s worked at Novo for more than 30 years and has been CEO for eight, will continue in the position for a period “to support a smooth transition to new leadership,” the company said.
The search for the next CEO is ongoing.
